Diasorin - Public Comps and Valuation Multiples

Diasorin Overview

About Diasorin

Diasorin develops and manufactures a broad portfolio of in vitro diagnostics used for detecting pathogens and contamination of samples from the human body, as well as used in industrial settings such as food and water contamination testing. The company operates three segments: immunodiagnostics (66% of sales), molecular diagnostics (17%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment’s importance has decreased over the years, and in 2024, it accounted for only 2% of total sales.

Founded

1968

HQ

Employees

3.3K+

Website

diasoringroup.com

Sectors

Laboratory Services
Medical Imaging & Diagnostics
BioTech
HealthTech

Financials

LTM Revenue $1.4B

LTM EBITDA $480M

EV

$5.4B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Diasorin Financials

As of September 2025, Diasorin reported last 12-month revenue of $1.4B and EBITDA of $480M.

In the same period, Diasorin generated $932M in LTM gross profit and $231M in net income.

See Diasorin valuation multiples based on analyst estimates

Diasorin P&L

In the most recent fiscal year, Diasorin reported revenue of $1.4B and EBITDA of $462M.

Diasorin expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Diasorin valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$1.4B	XXX	$1.4B	XXX	XXX	XXX
Gross Profit	$932M	XXX	$904M	XXX	XXX	XXX
Gross Margin	66%	XXX	66%	XXX	XXX	XXX
EBITDA	$480M	XXX	$462M	XXX	XXX	XXX
EBITDA Margin	34%	XXX	34%	XXX	XXX	XXX
EBIT	$356M	XXX	$307M	XXX	XXX	XXX
EBIT Margin	25%	XXX	22%	XXX	XXX	XXX
Net Profit	$231M	XXX	$218M	XXX	XXX	XXX
Net Margin	16%	XXX	16%	XXX	XXX	XXX
Net Debt	XXX	XXX	$686M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Diasorin including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $1.4B. EBITDA for the last twelve months was $480M. In the most recent fiscal year, Diasorin achieved $1.4B in revenue and $462M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$1.4B	Analyst estimates available to subscribers	$1.4B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$932M	Analyst estimates available to subscribers	$904M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	65.8% gross margin	Analyst estimates available to subscribers	65.9% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$480M	Analyst estimates available to subscribers	$462M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	33.9% EBITDA margin	Analyst estimates available to subscribers	33.7% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$356M	Analyst estimates available to subscribers	$307M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	25.1% EBIT margin	Analyst estimates available to subscribers	22.4% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$231M	Analyst estimates available to subscribers	$218M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	16.3% net profit margin	Analyst estimates available to subscribers	15.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$686M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Diasorin

This financial data table provides comprehensive performance metrics for Diasorin, a company based in Italy. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Diasorin generated $1.4B in revenue over the last twelve months.
The company achieved $480M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $932M.
Net income over the last twelve months reached $231M.

Fiscal Year Performance

In the most recent fiscal year, Diasorin reported $1.4B in total revenue.
Fiscal year EBITDA was $462M.
The company maintained a gross profit margin of 65.9% in the most recent fiscal year.
EBITDA margin for the fiscal year was 33.7%.
Net profit margin reached 15.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Diasorin. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Diasorin Stock Performance

Diasorin has current market cap of EUR 4.0B (or $4.7B), and EV of EUR 4.6B (or $5.4B).

Market Cap Evolution

Diasorin Stock Data

As of October 17, 2025, Diasorin's stock price is EUR 75 (or $87).

See Diasorin trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$5.4B	$4.7B	XXX	XXX	XXX	XXX	$4.82

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Diasorin Valuation Multiples

Diasorin's trades at 3.9x EV/Revenue multiple, and 11.6x EV/EBITDA.

See valuation multiples for Diasorin and 15K+ public comps

Diasorin Financial Valuation Multiples

As of October 17, 2025, Diasorin has market cap of $4.7B and EV of $5.4B.

Equity research analysts estimate Diasorin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Diasorin has a P/E ratio of 20.3x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$4.7B	XXX	$4.7B	XXX	XXX	XXX
EV (current)	$5.4B	XXX	$5.4B	XXX	XXX	XXX
EV/Revenue	3.8x	XXX	3.9x	XXX	XXX	XXX
EV/EBITDA	11.2x	XXX	11.6x	XXX	XXX	XXX
EV/EBIT	15.1x	XXX	17.5x	XXX	XXX	XXX
EV/Gross Profit	5.8x	XXX	n/a	XXX	XXX	XXX
P/E	20.3x	XXX	21.5x	XXX	XXX	XXX
EV/FCF	19.7x	XXX	19.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Diasorin Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Diasorin Margins & Growth Rates

Diasorin's last 12 month revenue growth is 7%

Diasorin's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.

Diasorin's rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Diasorin's rule of X is 51% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Diasorin and other 15K+ public comps

Diasorin Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	7%	XXX	6%	XXX	XXX	XXX
EBITDA Margin	34%	XXX	34%	XXX	XXX	XXX
EBITDA Growth	10%	XXX	7%	XXX	XXX	XXX
Rule of 40	39%	XXX	41%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	51%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.4M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	22%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	8%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	44%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial